Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials

Molecules, Journal Year: 2023, Volume and Issue: 28(13), P. 5145 - 5145

Published: June 30, 2023

Cancer continues to pose a severe threat global health, making pursuing effective treatments more critical than ever. Traditional therapies, although pivotal in managing cancer, encounter considerable challenges, including drug resistance, poor solubility, and difficulties targeting tumors, specifically limiting their overall efficacy. Nanomedicine's application cancer therapy signals new epoch, distinguished by the improvement of specificity, efficacy, tolerability treatments. This review explores mechanisms advantages nanoparticle-mediated delivery, highlighting passive active strategies. Furthermore, it transformative potential nanomedicine tumor therapeutics, delving into its applications across various treatment modalities, surgery, chemotherapy, immunotherapy, radiotherapy, photodynamic photothermal therapy, gene as well diagnosis imaging. Meanwhile, outlook therapeutics is discussed, emphasizing need for addressing toxicity concerns, improving delivery strategies, enhancing carrier stability controlled release, simplifying nano-design, exploring novel manufacturing technologies. Overall, integrating holds immense revolutionizing patient outcomes.

Language: Английский

---

Nanomaterial surface modification toolkit: Principles, components, recipes, and applications

Advances in Colloid and Interface Science, Journal Year: 2023, Volume and Issue: 322, P. 103035 - 103035

Published: Nov. 3, 2023

Surface-functionalized nanostructures are at the forefront of biotechnology, providing new opportunities for biosensors, drug delivery, therapy, and bioimaging applications. The modification significantly impacts performance success various applications by enabling selective precise targeting. This review elucidates widely practiced surface strategies, including click chemistry, cross-coupling, silanization, aldehyde linkers, active ester maleimide epoxy other protein DNA-based methodologies. We also delve into application-focused landscape nano-bio interface, emphasizing four key domains: therapeutics, biosensing, environmental monitoring, point-of-care technologies, highlighting prominent studies. insights presented herein pave way further innovations intersection nanotechnology a useful handbook beginners professionals. draws on sources, latest research articles (2018-2023), to provide comprehensive overview field.

Language: Английский

---

Advances in MicroRNA Therapeutics: from Preclinical to Clinical Studies

Human Gene Therapy, Journal Year: 2024, Volume and Issue: 35(17-18), P. 628 - 648

Published: Aug. 16, 2024

MicroRNAs (miRNAs) are crucial regulators of gene expression involved in various pathophysiological processes. Their ability to modulate multiple pathways simultaneously and their involvement numerous diseases make miRNAs attractive tools targets therapeutic development. Significant efforts have been made advance miRNA research the preclinical stage, attracting considerable investment from biopharmaceutical companies. Consequently, an increasing number miRNA-based therapies entered clinical trials for both diagnostic applications across a wide range diseases. While individual can regulate broad array mRNA targets, this also complicates management adverse effects seen trials. Several candidates discontinued due toxicity concerns, underscoring need comprehensive risk assessments therapeutics. Despite no strategies yet received approval regulatory agencies, prominent progress modulation approaches nano-delivery systems last decade, leading development novel safe well-tolerated drug candidates. In review, we present recent advances therapeutics currently or stages treating rare genetic disorders multifactorial common conditions. We address challenges related safety targeted delivery therapies, as well identification most effective

Language: Английский

---

Emerging Co‐Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal Neovascularization

Advanced Materials, Journal Year: 2024, Volume and Issue: 36(23)

Published: Feb. 12, 2024

Abstract Age‐related macular degeneration (AMD) disease has become a worldwide senile disease, and frequent intravitreal injection of anti‐vascular endothelial growth factor (anti‐VEGF) is the mainstream treatment in clinic, which associated with sight‐threatening complications. Herein, nintedanib, an inhibitor angiogenesis, lutein, potent antioxidant, can co‐assemble into nanoparticles through multiple noncovalent interactions. Interestingly, co‐assembled lutein/nintedanib (L/N NPs) exhibit significantly improved stability achieve long‐term sustained release two drugs for at least months mice. rabbit eyeball more complete barrier system, L/N NPs still successfully distribute retina choroid month. In laser‐induced mouse choroidal neovascularization model, after minimally invasive subconjunctival administration inhibit angiogenesis comparable even better therapeutic results to that standard anti‐VEGF. Therefore, drug behavior represents promising innovative strategy AMD treatment. Such together ability effectively reduce inflammation counteract oxidative stress holds great potential improving patient outcomes quality life those suffering from this debilitating eye condition.

Language: Английский

---

Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: Aug. 30, 2024

Camptothecin (CPT) is one of the frequently used small chemotherapy drugs for treating hepatocellular carcinoma (HCC), but its clinical application limited due to severe toxicities and acquired resistance. Combined chemo-gene therapy has been reported be an effective strategy counteracting drug resistance while sensitizing cancer cells cytotoxic agents. Thus, we hypothesized that combining CPT with miR-145 could synergistically suppress tumor proliferation enhance anti-tumor activity.

Language: Английский

---

Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(17)

Published: Feb. 26, 2024

As an indispensable part of the human sensory system, visual acuity may be impaired and even develop into irreversible blindness due to various ocular pathologies. Among diseases, fundus neovascularization diseases (FNDs) are prominent etiologies impairment worldwide. Intravitreal injection anti-vascular endothelial growth factor drugs remains primary therapy but is hurdled by common complications incomplete potency. To renovate current therapeutic modalities, nanomedicine emerged as times required, which endowed with advanced capabilities, able fulfill effective drug delivery achieve precise release control, thus further improving effect. This review provides a comprehensive summary advances in for FND management from state-of-the-art studies. First, modalities FNDs thoroughly introduced, focusing on key challenges delivery. Second, nanocarriers comprehensively reviewed posterior based nanostructures: polymer-based nanocarriers, lipid-based inorganic nanoparticles. Thirdly, characteristics microenvironment, their pathological changes during FNDs, corresponding strategies constructing smart elaborated. Furthermore, prospects discussed.

Language: Английский

---

A Sustainable Retinal Drug Co‐Delivery for Boosting Therapeutic Efficacy in wAMD: Unveiling Multifaceted Evidence and Synergistic Mechanisms

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(14)

Published: Feb. 22, 2024

Abstract Sustainable retinal codelivery poses significant challenges technically, although it is imperative for synergistic treatment of wet age‐related macular degeneration (wAMD). Here, a microemulsion‐doped hydrogel (Bor/PT‐M@TRG) engineered as an intravitreal depot composing temperature‐responsive (TRG) and borneol‐decorated paeoniflorin (PF) & tetramethylpyrazine (TMP)‐coloaded microemulsions (Bor/PT‐M). Bor/PT‐M@TRG, functioning the “ammunition depot”, resides in vitreous continuously releases Bor/PT‐M therapeutic “bullet”, enabling deep penetration into retina 21 days. A single injection Bor/PT‐M@TRG yields substantial reductions choroidal neovascularization (CNV, hallmark feature wAMD) progression mitigates oxidative stress‐induced damage vivo. Combinational PF&TMP regulates “reactive oxygen species/nuclear factor erythroid‐2‐related 2/heme oxygenase‐1” pathway blocks “hypoxia inducible factor‐1α/vascular endothelial growth factor” signaling retina, synergistically cutting off loop CNV formation. Utilizing fluorescence resonance energy transfer liquid chromatography‐mass spectrometry techniques, they present compelling multifaceted evidence sustainable spanning formulations, ARPE‐19 cells, vivo eye balls, ex section/retina‐choroid complex cell levels. Such approach elucidated key driving force behind exceptional outcomes Bor/PT‐M@TRG. These findings highlight significance drug rational combination effective wAMD.

Language: Английский

---

Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Language: Английский

---

Utilization of Nanoparticles for Treating Age-Related Macular Degeneration

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 162 - 162

Published: Jan. 25, 2025

Age-related macular degeneration (AMD) is a predominant cause of vision loss, posing significant challenges in its management despite advancements such as anti-vascular endothelial growth factor (anti-VEGF) therapy. Nanomedicine, with novel properties and capabilities, offers promising potential to transform the treatment paradigm for AMD. This review reports use diverse nanoparticles (NPs) AMD vitro, vivo, ex including liposomes, lipid nanoparticles, nanoceria, nanofibers, magnetic quantum dots, dendrimers, polymer delivered forms gels, eye drops, intravitreally, or intravenously. Drug delivery was most common NPs AMD, followed by photodynamic therapy dose enhancement, antioxidant function biomimetic activity, immune modulation. Innovative approaches arising included nanotechnology-based light-responsive controlled drug release, well gene transfer. Nanomedicine transformative approach applications. The integration nanotechnology not only provides innovative solutions overcome current therapeutic limitations but also shows enhancing outcomes patient quality life.

Language: Английский

---

Retinopathy of Prematurity and MicroRNAs

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 400 - 400

Published: Feb. 7, 2025

Retinopathy of Prematurity (ROP), a leading cause blindness in preterm infants, arises from dysregulated angiogenesis and inflammation. Without timely intervention, ROP can progress to severe outcomes, including dense fibrovascular plaques retinal detachment. MicroRNAs (miRNAs) regulate key pathways such as hypoxia response, VEGF signaling, vascular remodeling. Studies have identified miRNAs (e.g., miR-210, miR-146a, miR-21) potential biomarkers therapeutic targets. Preclinical evidence supports miRNA-based therapies miR-18a-5p miR-181a), targeting HIF-1α VEGFA mitigate neovascularization, with nanoparticle delivery systems enhancing stability specificity. These strategies, combined anti-VEGF agents, show significant for improving management. While promising, miRNA require validation clinical trials ensure safety efficacy. This review discusses the role ROP, highlighting their relevance diagnostic tools.

Language: Английский

---